,

Rev Esp Quimioter 2024; 37(1): 69-77

In vitro activity of cefiderocol and other newly approved antimicrobials against multi-drug resistant Gram-negative pathogens recovered in intensive care units in Spain and Portugal

DESIREE GIJÓN, MARÍA GARCÍA-CASTILLO, MARÍA DEL CARMEN FERNÁNDEZ-LÓPEZ, GERMÁN BOU, MARÍA SILLER, JORGE CALVO-MONTES, CRISTINA PITART, JORDI VILA, NURIA TORNO, CONCEPCIÓN GIMENO, HUGO CRUZ, HELENA RAMOS, XAVIER MULET, ANTONIO OLIVER, PATRICIA RUIZ-GARBAJOSA, RAFAEL CANTON

Published: 26 October 2023

http://www.doi.org/10.37201/req/098.2023

Introduction. The antimicrobial resistance is a significant public health threat, particularly for healthcare-associated infections caused by carbapenem-resistant Gram-negative pathogens which are increasingly reported worldwide. The aim of this study was to provide data on the in vitro antimicrobial activity of cefiderocol and that of commercially available comparator antibiotics against a defined collection of recent clinical multi-drug resistant (MDR) microorganisms, including carbapenem resistant Gram-negative bacteria collected from different regions in Spain and Portugal.
Material and methods. A total of 477 clinical isolates of Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia were prospectively (n=265) and retrospectively (n=212) included (2016-2019). Susceptibility testing was performed using standard broad microdilution and results were interpreted using CLSI-2021 and EUCAST-2021 criteria.
Results. Overall, cefiderocol showed a good activity against Enterobacterales isolates, being 99.5% susceptible by CLSI and 94.5% by EUCAST criteria. It also demonstrated excellent activity against P. aeruginosa and S. maltophilia isolates, all being susceptible to this compound considering CLSI breakpoints. Regarding A. baumannii (n=64), only one isolate was resistant to cefiderocol.
Conclusions. Our results are in agreement with other studies performed outside Spain and Portugal highlighting its excellent activity against MDR gram-negative bacteria. Cefiderocol is a therapeutic alternative to those available for the treatment of infections caused by these MDR bacteria.

Rev Esp Quimioter 2024; 37(1): 69-77 [Full-text PDF] [Supplementary material PDF]


</a

,

Rev Esp Quimioter 2023; 36(6): 597-603

Evolution of the serotypes causing invasive pneumococcal disease along 2008-2022 in a Level 2 Public Hospital of the Madrid Region, in relation to their inclusion in different conjugate vaccines

GLORIA ZARAGOZA VARGAS, JUANA CACHO CALVO, RODRIGO MARTÍNEZ-ARCE, DAVID MOLINA ARANA, BELÉN RAMOS BLÁZQUEZ, MARTA PÉREZ ABELEDO, JUAN CARLOS SANZ MORENO

Published: 24 October 2023

http://www.doi.org/10.37201/req/034.2023

Introduction. The use of conjugate vaccines against Streptococcus pneumoniae originates changes in the invasive pneumococcal disease (IPD). The aim of this study was to in vestigate the evolution of S. pneumoniae serotypes isolated in the Hospital Universitario de Getafe between 2008 and 2022.
Material and Methods. 313 of S. pneumoniae strains were studied. Serotyping was carried out by latex agglutination (Pneumotest-latex) and the Quellung reaction. In addition, the minimal inhibitory concentration (MIC) was determined against penicillin, erythromycin and levofloxacin by the concentration gradient method (E-test) according the EUCAST breakpoints.
Results. The most frequent serotypes throughout the study period were 8, 3, 19A, 1, 11A and 22F corresponding to 46.6% of the isolates. Along 2008-2012 the serotypes 3, 1, 19A, 7F, 6C and 11A represented altogether 53.6% of the isolates. Between 2013 and 2017 the serotypes 3, 8, 12F, 19A, 22F and 19F grouped 51% of the isolates. During 2018-2022 the serotypes 8, 3, 11A, 15A, 4 and 6C included the 55.5% of the cases. In total 5 strains (1.6%) were penicillin resistant, 64 (20.4%) erythromycin resistant and 11 (3.5%) levofloxacin resistant. The MIC50 and MIC90 levels maintained stables along the time.
Conclusion. The conjugate vaccines use with different serotype coverage conditioned a decrease of the vaccine-included and an increase of non-covered. Despite these changes, the global antimicrobial susceptibility patterns to erythromycin and levofloxacin maintained relatively stables. The resistance a penicillin was low, not finding this type of resistant strains in the last study period.

Rev Esp Quimioter 2023; 36(6): 597-603 [Texto completo PDF]


</a

,

Rev Esp Quimioter 2023; 36(6): 645-647

Definiendo nuevos escenarios terapéuticos para oritavancina: severa infección bacteriémica de piel y partes blandas por Staphylococcus aureus en una paciente oncológica intensamente inmunodeprimida

JAVIER MORENO IZARRA, ANNE BRUNST, JOSE ANTONIO CARMONA ÁLVAREZ, FRANCISCO ARANDA, JUAN MANUEL MÁRTIR ALARIO

Published: 11 October 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/055.2023

Rev Esp Quimioter 2023; 36(6): 645-647 [Texto completo PDF]


</a

,

Rev Esp Quimioter 2023; 36(6): 648-650

Estudio comparativo de dos métodos de detección frente al virus Monkeypox: antígeno y PCR

MARÍA GARCÍA GONZÁLEZ, JORGE-ALFREDO PÉREZ-GARCÍA, ESTHER CULEBRAS LÓPEZ, BEGOÑA BAZA CARACIOLO, EVA ORVIZ GARCÍA, MAR VERA GARCÍA, ALBERTO DELGADO-IRIBARREN GARCÍA

Published: 6 October 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/057.2023

Rev Esp Quimioter 2023; 36(6): 648-650 [Texto completo PDF]

,

Rev Esp Quimioter 2023; 36(6): 638-640

Infección de prótesis articular por Clostridioides difficile y revisión de la literatura

SARA ASTOR MOLERO, NURIA VÁZQUEZ-TEMPRANO, PABLO CAMACHO ZAMORA, XACOBE SOLA MALLO, PATRICIA ÁLVAREZ GARCÍA, JUAN CARLOS RODRÍGUEZ GARCÍA

Published: 10 October 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/037.2023

Rev Esp Quimioter 2023; 36(6): 638-640 [Texto completo PDF]


</a

,

Rev Esp Quimioter 2023; 36(6): 655-657

Association of nirmatrelvir/ritonavir and remdesivir as treatment for SARS-CoV-2 infection in immunocompromised patients with hematologic malignancies. Series of four cases

ANA SEGURA FÁBREGA, IGNACIO PÉREZ CATALÁN, IRIS GÓMEZ ALFARO, SERGIO GARCÍA MUÑOZ, CELIA ROIG MARTÍ, NOELIA RODRÍGUEZ LOZANO, SOFÍA FOLGADO ESCUDERO, MARÍA VAREA VILLANUEVA, ADRIANA GASCÓN BUJ, MIGUEL TORRES GARCÍA, ROBERTO REIG VALERO, RAÚL FERRANDO PIQUERES, JORGE USÓ BLASCO

Published: 3 October 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/069.2023

Rev Esp Quimioter 2023; 36(6): 655-657 [Full-text PDF]


</a

,

Rev Esp Quimioter 2023; 36(6): 621-624

Evaluation of two phenotypic techniques and a commercial multiplex molecular panel for the detection of different carbapenemases

NOELIA HERNANDO PARREÑO, ÁNGELES SAMPERE MARTÍNEZ

Published: 3 October 2023

http://www.doi.org/10.37201/req/049.2023

Introduction. The prevalence of carbapenemase-producing Enterobacterales has increased in recent years and is considered an important public health problem.
Material and methods. A total of 106 clinical samples were analyzed by different carbapenemase detection techniques: inhibition discs (ID), immunochromatographic test (ICT) and a genotypic method, comparing them with a multiplex RT-PCR as a reference method.
Results. Overall, all 3 techniques exceeded 90% sensitivity, although with differences in the performance of some of them by carbapenemase type. DI had low specificity (62%) for OXA-48, while with TIC the sensitivity for NDM-type metallo-beta-lactamase (93%) was slightly lower than for OXA-48 (95%). The best results were obtained with the genotypic technique (100% overall performance).
Conclusions. Despite the lower sensitivity of TICs (especially in NDM carbapenemases) compared to molecular techniques, with the modification of the protocol we managed to increase this sensitivity and, together with the lower price, simplicity and speed, it makes this technique a good screening option.

Rev Esp Quimioter 2023; 36(6): 621-624 [Texto completo PDF]


</a

,

Rev Esp Quimioter 2023; 36(6): 651-654

Uveítis complicada por Scedosporium apiospermum sensu estricto: relevancia del diagnóstico precoz y su manejo multidisciplinar

SARA HERNÁNDEZ EGIDO, BLANCA BENITO-PASCUAL, PAULA HERNÁNDEZ CALVO, LUISA VIZUETE-RODRÍGUEZ, ÓSCAR MANUEL MUÑOZ CLEMENTE, MARÍA SOLEDAD CUÉTARA

Published: 2 October 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/064.2023

Rev Esp Quimioter 2023; 36(6): 651-654 [Texto completo PDF]


</a

,

Rev Esp Quimioter 2023; 36(6): 643-644

Is Mycobacterium shimoidei an under-recognized cause of tuberculosis-like disease?

LAURA ALONSO ACERO, INMACULADA QUILES-MELERO, MARÍA JESÚS JARAS-HERNÁNDEZ, CARLOS TORO

Published: 2 October 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/054.2023

Rev Esp Quimioter 2023; 36(6): 643-644 [Full-text PDF]


</a

,

Rev Esp Quimioter 2023; 36(6): 641-642

Infección cutánea por Bacillus licheniformis

LAURA RITA IOTTI, LUCÍA PUENTE-FUERTES, MÓNICA DE FRUTOS, ANTONIO GONZALEZ-LOPEZ, JOSÉ M. EIROS

Published: 2 October 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/040.2023

Rev Esp Quimioter 2023; 36(6): 641-642 [Texto completo PDF]


</a